MedTrace Logo

Safety of and Immune Response to a Prime-Boost Vaccine Regimen in HIV-Uninfected Vaccine-Naive Adults

NCT00820846 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 299

Last updated 2022-08-09

No results posted yet for this study

Summary

The purpose of this study is to evaluate the safety of and immune response to a two-vaccine regimen in healthy, HIV-uninfected adults who have never received an HIV preventive vaccine before.

Conditions

  • HIV Infections

Interventions

BIOLOGICAL

pGA2/JS7 DNA vaccine

1 mL of pGA2/JS7 DNA vaccine

BIOLOGICAL

Placebo

1 mL of sodium chloride for injection

BIOLOGICAL

MVA/HIV62 vaccine

1 mL of recombinant modified vaccinia Ankara/HIV clade B gag-pol-env (MVA/HIV62)

Sponsors & Collaborators

  • National Institute of Allergy and Infectious Diseases (NIAID)

    lead NIH

Principal Investigators

  • Paul A Goepfert, MD · UAB, Div. of Infectious Diseases

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2009-01-31
Primary Completion
2012-08-31
Completion
2014-09-30

Countries

  • United States
  • Peru

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00820846 on ClinicalTrials.gov